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2014, accepted Feupply/demand (type 2) myocardial infarction is a commonly encountered clinical challenge. It is anticipated that it
will be detected more frequently once high-sensitivity cardiac troponin assays are approved for clinical use in the
United States. We provide a perspective that is based on available data regarding the deﬁnition, epidemiology,
etiology, pathophysiology, prognosis, management, and controversies regarding type 2 myocardial infarction.
Understanding these basic concepts will facilitate the diagnosis and treatment of these patients as well as ongoing
research efforts. (J Am Coll Cardiol 2014;63:2079–87) ª 2014 by the American College of Cardiology FoundationIn 2007, the second Universal Deﬁnition of myocardial
infarction (MI) introduced and deﬁned ﬁve different MI
subtypes that were endorsed by the major cardiology socie-
ties (1). Type 1 MI (T1MI) corresponds to a spontaneous
MI secondary to atherosclerotic plaque rupture, ulceration,
ﬁssuring, erosion, or dissection with resulting intraluminal
thrombus leading to decreased myocardial blood ﬂow or distal
platelet emboli with consequent myocyte necrosis (acute
coronary syndrome, [ACS]), whereas type 2 MI (T2MI)
was deﬁned as MI due to supply/demand mismatch,
without plaque rupture, but also with myocardial necrosis
evidenced by a rise and/or fall of cardiac biomarkers above
the 99th percentile reference value of a normal population,
in addition to at least one of the other criteria for MI (2).
For numerous reasons, there is controversy and reluctance
to use the term “T2MI” in clinical practice. Foremost,
although the ACS classiﬁcation of ST-segment elevation
myocardial infarction (STEMI), non–ST-segment elevation
myocardial infarction (NSTEMI), and unstable angina is
widely adopted to guide revascularization and pharma-
cological treatment, not all have embraced the 5-MI sub-
type classiﬁcation (1–6). Notably, recognizing limited
availability of some cardiac biomarkers in many settings, the
World Health Organization deﬁnition of MI limits its
discussion on supply/demand MI (4). Another motive for
the reluctance relies on the basis that the Internationaln of Cardiology, Department of Medicine, Hennepin County
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bruary 11, 2014.Classiﬁcation of Diseases coding system does not recognize
T2MI, and often MI quality review programs (e.g., Centers
for Medicaid and Medicare Services) rigorously evaluate for
certain measures for anyone with a diagnosis of acute MI,
which may be appropriate for ACS (T1MI), but may not be
appropriate for an MI (T2MI) not caused by ACS (7).
Distinguishing different etiologies of ischemic myocar-
dial necrosis is essential for clinical purposes, mainly because
management differs when cardiac troponin (cTn) is elevat-
ed as the result of T1MI, as opposed to T2MI (5,6). The
purpose of this article is to provide an evidence-based per-
spective on supply/demand T2MI.
Deﬁnition
The Third Universal Deﬁnition of MI consensus document
deﬁnes MI by the evidence of myocardial necrosis in a
clinical setting consistent with acute myocardial ischemia, in
which there is a rise and/or fall of cTn with at least one value
above the 99th percentile of a normal reference population;
and the presence of at least one of the following: a) ischemic
symptoms; b) new or presumed new signiﬁcant ST-segment
or T-wave changes or new left bundle-branch block; c)
development of pathological Q waves in the electrocardio-
gram; d) imaging evidence of new loss of viable myocardium
such as a new regional wall motion abnormality; or e) iden-
tiﬁcation of an intracoronary thrombus by means of angio-
graphy or autopsy (2).
On the basis of the above criteria, T2MI is diagnosed in
instances in which a supply/demand imbalance leads to
myocardial injury with necrosis that is not caused by ACS,
including arrhythmias, aortic dissection, severe aortic valve
disease, hypertrophic cardiomyopathy, shock, respiratory
failure, severe anemia, hypertension with or without left
ventricular hypertrophy, coronary spasm, coronary embolism
or vasculitis, and coronary endothelial dysfunction without
signiﬁcant coronary artery disease (CAD) (2,8).
Abbreviations
and Acronyms
ACS = acute coronary
syndrome(s)
CAD = coronary artery
disease
cTn = cardiac troponin
ED = emergency department
MI = myocardial infarction
NSTEMI = non–ST-segment
elevation myocardial
infarction
STEMI = ST-segment
elevation myocardial
infarction
T1MI = type 1 myocardial
infarction
T2MI = type 2 myocardial
infarction
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2080It should be noted that in
contrast with the 2007 Universal
Deﬁnition of MI, the 2012 rec-
ommendations incorporated co-
ronary endothelial dysfunction as
one of the variables to consider
when encountering supply/demand
ischemia (1,2). Coronary endo-
thelial dysfunction has been asso-
ciated with myocardial ischemia
and increased cardiac events, and
certainly these patients may have
cTn increases and meet the deﬁ-
nition for MI (9–11). However, it
is unclear if endothelial-dependent
coronary ﬂow reserve assessment
with acetylcholine infusion is war-
ranted in the acute MI setting.
From an electrocardiographic
perspective, the use of the terms
NSTEMI and STEMI has been applied to T2MI. Saaby
et al. (12) recently reported 144 T2MI, of which 3.4% were
categorized as STEMI and 96.6% as NSTEMI (12). The
signiﬁcance of applying these electrocardiographic classiﬁ-
cations to T2MI is unclear, as they are clinically intended to
guide reperfusion therapy in T1MI (ACS) (5,6).
The interpretation of cTn increases in conditions in which
supply/demand is being considered can be challenging, largely
due to the paucity of speciﬁc criteria for what exactly con-
stitutes a T2MI. Several major expert opinion documents
have provided some guidance in regard to what should be
considered a T2MI, but none of these documents have
deﬁned speciﬁc criteria for T2MI (2,8,13).
Saaby et al. (12) have proposed certain novel, speciﬁc
criteria for T2MI, in order to avoid the implicit subjectivity
in the clinical diagnosis (criteria detailed in Table 1).
However, the development of strict criteria for the diagnosis
of T2MI is complicated by the multifactorial nature of
supply/demand ischemia, as patients may have any number
of factors leading to increased demand or decreased supply,
which in addition may or may not be in the setting of
distinct pre-existing conditions such as ﬂow-limiting CAD.
Thus, advocating for any strict criteria and cutoffs of vari-
ables such as heart rate or blood pressure may have its own
limitations. Most studies have used adjudicators who can
assess all contributing variables and give a subjective diag-
nosis of T2MI without applying strict parameters.
Among patients with no pre-existing conditions such
as underlying CAD, a clearly recognizable acute and/or
sustained supply/demand mismatch should be present to
consider T2MI. Conversely, in patients with underlying
comorbidities such as signiﬁcant CAD and/or the presence
of several supply/demand imbalances, lower thresholds of
supply/demand mismatches may be required to elicit is-
chemia. In these patients, an individualized diagnostic
approach should be favored.The current “gold-standard” deﬁnition for T2MI remains
undetermined, and any future MI consensus document
should ideally provide further clariﬁcation in this challeng-
ing area to guide both clinicians and researchers and bring
homogeneity to this ﬁeld. Details including deﬁnitions used
across selected heterogeneous studies, which have reported
T2MI, are summarized in Table 1.
Epidemiology
With the use of current contemporary cTn assays, T2MI
is frequently encountered in clinical practice (Table 1). It
is expected that after the anticipated Food and Drug
Administration (FDA) clearance (likely 2014) of high-
sensitivity cTn assays, these assays will be as commonly
used in clinical practice in the United States, as they
currently are in the rest of the world. This use will likely lead
to an increased incidence of cTn elevations above the 99th
percentile in clinical settings consistent with T2MI (14).
However, little epidemiologic data is available on T2MI,
possibly due to the relatively recent introduction of this term,
suspected underreporting, and confusion as to what specif-
ically constitutes a T2MI given lack of speciﬁc criteria.
There are a limited number of studies addressing the
frequency of T2MI. Morrow et al. (15) described the value
of the Universal Deﬁnition of MI in the context of a clinical
trial. In follow-up of 1,218 MIs, T2MI was infrequent and
consisted of 3.5% (n ¼ 43) of all MIs, in contrast to 32.6%
T1MI and 49.5% (n ¼ 603) peri-percutaneous coronary
intervention (type 4A) MI. This study was limited because
it was an ACS trial, which included a pre-selected popula-
tion, and therefore was not reﬂective of the true epide-
miology of T2MI. Javed et al. (16) performed a prospective
study to identify the percentage of hospitalized patients with
a positive cTn who fulﬁlled the criteria for MI and classiﬁed
them according to the Universal Deﬁnition using a con-
temporary, sensitive cTn assay (ADVIA TnI-Ultra, 99th
percentile: 40 ng/l) over a 3-month period. In this large,
prospective study, cTnI was obtained in 2,979 patients, with
701 having at least one increased cTnI: 216 had MI ac-
cording to the Universal Deﬁnition of MI, of which 143
(66.2%) had a T1MI and 64 (29.6%) had T2MI (the
remaining 4.2% [n ¼ 9] were type 3 and 4 MI). Melberg et
al. (17) studied the implications of the Universal Deﬁnition
of MI by retrospectively studying all patients hospitalized
in 2004 with suspected MI using the 4th generation Roche
cTnT assay. Their cohort of 1,093 patients with MI consisted
of 967 (88.5%) with T1MI and 17 (1.6%) with T2MI (the
remaining 9.9% [n ¼ 109] were classiﬁed as type 3 to 5 MI).
Smith et al. (18), in a retrospective study of 662 consec-
utive patients with ischemic symptoms presenting to the
emergency department (ED) in which cTnI was obtained
with the use of the Siemens Stratus CS (Tarrytown, New
York) (99th percentile: 99 ng/l), found that of 139 who had
MI, 40 (28.8%) had T1MI and 99 (71.2%) had T2MI. In
a subsequent study at the same institution, among 1,119
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2081consecutive patients presenting to the ED who had serial
cTnI measured (Ortho-Clinical Diagnostics cTnI contem-
porary assay; 99th percentile, 34 ng/l), T1MI occurred in
106 patients (9.5% of the total population, 37.9% of total
MIs; STEMI [n ¼ 29], NSTEMI [n ¼77]) and T2MI in
174 patients (15.5% of the total population, 62.1% of total
MIs); cTnI concentrations were higher in NSTEMI
(T1MI) versus T2MI at both 0 and 6 hours (p ¼ 0.01), with
a trend at 3 h (p ¼ 0.08) (19).
Saaby et al. (12) assessed the frequency of T2MI, deﬁning
it by non-guideline clinical standards using a contemporary
cTnI assay (Architect, 99th percentile 28 ng/l). Using their
distinct approach in which speciﬁc criteria were delineated to
qualify as a T2MI, 553 patients had an MI, of which 397
(71.8%) had T1MI and 144 (26%) had T2MI. The
remaining 2.2% (n ¼ 12) were type 4 and 5 MIs. For cTnI
concentrations, T2MI had signiﬁcantly lower peak cTnI
values in comparison to T1MI (1.09 mg/l vs. 2.96 mg/l,
p < 0.001).
Remarkably, several studies report very low T2MI fre-
quencies. These studies are limited by selection bias, as the
selected study population (e.g., retrospective or prospective
analyses on patients with an ACS diagnosis) favors T1MI
(ACS) frequency (15,20,21). Conversely, studies using a less
selected approach reported much higher T2MI frequencies
(12,16,19).
Frequencies and cTn assays that were used across studies
focusing on T2MI are shown in Table 1. Review of these
studies demonstrates that despite a proposed deﬁnition
of T2MI by the Universal Deﬁnition consensus, there
is no validated reproducible deﬁnition by which to make
a consistent diagnosis. It remains challenging to adjudicate
T1MI versus T2MI for research, clinical, and regulatory
purposes because there are no consistently accurate and reli-
able criteria for the diagnosis (22).
The disparity in diagnosis deﬁnitions, variations in ad-
judication processes, along with differences in cTn assays
and cutoff values used, as well as the studied population
(e.g., patients with chest pain in the ED vs. unselected
hospitalized patients, etc.) complicates the epidemiological
evaluation of T2MI and is reﬂected in the heterogeneous
prevalence of T2MI shown in Table 1.
We opine that the included study population, as well
as the speciﬁc patients in which cTn is being measured
also plays a signiﬁcant role in the heterogeneous T2MI
prevalence. Despite recommendations suggesting that cTn
evaluation should be performed only if clinically indicated
for suspected MI, in clinical practice many cTn measure-
ments are obtained in a wide variety of clinical situations,
many of which have a very low pretest probability of T1MI
(8). This may be explained by the “fear” of missing T1MI
presenting with atypical symptoms, as over 25% of patients
with ACS complain of a symptom other than chest pain,
such as abdominal pain or dyspnea (23). The serious lia-
bilities related to failure to diagnose and treat ACS may
tempt physicians to obtain cTn in several “atypical”situations with low pretest probability for ACS. The vari-
ability in cTn measurement patterns across medical centers
likely contributes to the heterogeneous T2MI prevalence.
Additionally, clinicians may obtain cTn, even in the absence
of ACS, because of its prognostic value in other non-ACS
conditions (e.g., pulmonary embolism) (14). The conse-
quences of testing a broader unselected population may have
resource utilization, therapeutic, and ﬁnancial implications,
which are not well understood.
Etiology and Pathophysiology of Type 2 MI
Numerous pathologies can cause disequilibrium in the
balance between oxygen supply and demand. This balance
is a critical determinant of the normal cardiac function, and
understanding the variables involved is fundamental to
understand the ischemic response in T2MI (24). Myocar-
dial oxygen demand relies on three major determinants:
systolic wall tension, contractility, and heart rate, whereas
myocardial oxygen supply relies on the coronary blood ﬂow
and oxygen-carrying capacity (24–26). Disequilibrium in
the myocardial supply and demand caused by alteration of
the factors involved in these complex hemodynamic in-
teractions may lead to myocardial ischemia. For example,
both hypoxia and anemia can decrease oxygen carrying
capacity, leading to an imbalance secondary to supply
mismatch. This may result in ischemia, which, if severe
enough, may lead to myocardial cell death with symptoms
and/or ECG changes and release of cTn. If cTn exceeds
the 99th percentile and there is a rising and/or falling
pattern in conjunction with any other MI criteria in the
absence of plaque rupture, this would then be, by deﬁnition,
a T2MI. It is also important to note that stable CAD, with
signiﬁcant stenosis, may limit coronary blood ﬂow, leading
to ischemia under conditions of increased oxygen demand
or decreased supply.
Based on these concepts, any mismatch may be explained
by a similar pathophysiologic approach. Overall, in a clinical
setting consistent with myocardial ischemia coincident with
a rise and/or fall in cTn, if a clinician cannot readily identify
any clear “alternate” factor that would alter this supply/de-
mand balance, one must be cautious before labeling an MI as
T2MI. Moreover, to further complicate matters, patients
may manifest more than one type of MI simultaneously or
sequentially (1).
Without any systematic data, an accurate estimate of
the various etiologies that can lead to T2MI is limited and
subject to misinterpretation. An analysis assessing the
frequency of T2MI showed that anemia, tachyarrhyth-
mias, and respiratory failure were the most common
conditions predisposing to T2MI (12).
There are certain scenarios in which distinguishing T1MI
from T2MI might be particularly challenging, such as the
post-operative setting, heart failure, end-stage renal disease,
sepsis, and the critically ill (2,13,27–33). In patients with
heart failure, cTn is often increased and occurs either in a
Table 1 Summary of Selected Type 2 MI Studies
Fisrt Author
(Ref. #) Type 2 MI Study Deﬁnition Studied Population
Total
MIs
T1MI,
n (%)
T2MI,
n (%)
Troponin Assay:
Category
(LoD, 99th URL, CV)
Morrow
(15)
Secondary MI caused by either
increased oxygen demand or
decreased supply (e.g., coronary
artery spasm or anemia).
Adjudicated diagnoses.
Each clinical end points committee–
determined MI underwent
supplemental classiﬁcation
according to the Universal
Deﬁnition of MI.
Patients from original ACS trial
followed for new or recurrent
MIs (1,118 patients) (distinct
from index event).
1,218 397 (32.6%) 43 (3.5%) Details of each
local assay
manufacturer and
platform were
not collected in
this trial. URL was
deﬁned by the MI
limit reported by
each local
laboratory.
Javed
(16)
Supply demand alterations in
myocardial perfusion because
of coronary spasm, embolism,
arrhythmia, anemia, hypotension,
or hypertension.
For type 2 MI, clinical ischemia was
present but no culprit lesion was
visualized if angiography was
performed and/or there was a
documented disturbance in
supply/demand.
Diagnosis of type 1 AMI required
clinical ischemia and a culprit
lesion visualized on angiogram
and/or absence of documentation
of a condition associated with
decreased supply or increased
demand such as a
tachyarrhythmia or hypotension.
Adjudicated diagnoses.
All adult patients hospitalized
who had >1 abnormal cTnI
level admitted through the
emergency room, from
inpatient service, or
transferred into hospital.
There were 701 patients
evaluated for increased cTn,
of whom 216 had AMI by
universal deﬁnition.
216 143 (66.2%) 64 (29.6%) Siemens ADVIA Ultra
cTnI.
LoD and CV: NR
99th URL: 40 ng/l
Melberg
(17)
AMI secondary to increased oxygen
demand or decreased supply
(anemia, arrhythmias,
hypotension).
Adjudicated diagnoses of reviewed
cases.
During the year 2004, subjects
were identiﬁed by AMI
discharge diagnosis, elevated
cTn, patients undergoing
revascularization, and sudden
death possibly caused by AMI.
All patients with a condition
that could possibly satisfy the
2007 AMI deﬁnition were
categorized accordingly
(patients with ICD-10 AMI
discharge diagnosis, cTnT-
positive patients without
ICD-10 discharge diagnosis,
revascularized patients with
normal baseline TnT, and
patients with cardiac arrest
with ECG and ﬁndings
suggestive of AMI dying
without proven cTnT elevation).
1,093 967 (88.5%) 17 (1.6%) Roche Elecsys
2010 cTnT.
CV: 10% at 30 ng/l
URL: 30 ng/l
Continued on the next page
Sandoval et al. JACC Vol. 63, No. 20, 2014
Supply/Demand Type 2 Myocardial Infarction May 27, 2014:2079–87
2082non-MI setting or may be related to either a T1MI or
T2MI. It has been described that T2MI in the setting of
heart failure may be caused by small-vessel coronary ob-
struction, increased transmural pressure, endothelial dys-
function, and/or supply/demand mismatch related to
subendocardial ischemia alone (2,28).
In the post-operative setting, myocardial oxygen supply/
demand balance can be easily altered and lead to a periop-
erative MI. Post-operative oxygen supply/demand imbal-
ance is most commonly caused by tachycardia, although
many other scenarios can lead to a mismatch, includinghemorrhage-related hypotension, hypertension in the setting
of elevated stress hormones, anemia, and hypoxemia, among
other conditions (27).
Among critically ill patients in the intensive care unit and
individuals with sepsis, the etiologic assessment of cTn in-
creases is remarkably difﬁcult. Many patients are sedated
and intubated, which impedes any direct ischemic symptom
evaluation, which is an essential MI criterion. Additionally,
cTn elevations may not only be due to T1MI or T2MI but
also mediated by circulating substances (sepsis-induced),
vasopressors, and catecholamine toxicity (2,32,33).
Table 1 Continued
Fisrt Author
(Ref. #) Type 2 MI Study Deﬁnition Studied Population
Total
MIs
T1MI,
n (%)
T2MI,
n (%)
Troponin Assay:
Category
(LoD, 99th URL, CV)
Saaby
(12)
Type 2 MI secondary to myocardial
ischemia resulting from increased
oxygen demand or decreased
supply.
Authors developed speciﬁc clinical
standards for the deﬁnition of
type 2 MI.
Decreased supply:
Hemoglobin <5.5 mmol/l for men
and <5.0 mmol/l for women.
Shock deﬁned as systolic blood
pressure <90 mm Hg together with
signs of organ dysfunction.
Bradyarrhythmia requiring medical
treatment or cardiac pacing.
Coronary embolus in the presence
of an increased risk of embolism.
Respiratory failure with an arterial
oxygen tension <8 kPa and clinical
signs of respiratory failure lasting
>20 min.
Increased demand:
Ventricular tachyarrhythmia lasting
>20 min
Supraventricular tachyarrhythmia
lasting >20 min
Hypertensive pulmonary edema
deﬁned as systolic blood pressure
>160 mm Hg, signs of pulmonary
edema, and a need for treatment
with nitrates or diuretics.
Arterial hypertension with a
systolic blood pressure >160
mm Hg and concomitant left
ventricular hypertrophy identiﬁed
by echocardiography or
electrocardiogram.
Prospective study of unselected
hospital patients who had a
cTnI measured on clinical
indication.
553 397 (71.8%) 144 (26%) Abbott Architect cTnI.
LoD: 10 ng/l
99th URL: 28 ng/l
CV <10% at 32 ng/l
Decision limit for
MI diagnosis:
>30 ng/l
Nelson
(19)
Type 2 MI was deﬁned as MI
secondary to ischemia caused by
either increased oxygen demand
or decreased supply, for example
coronary artery spams, coronary
embolism, anemia, arrhythmias,
hypertension, or hypotension.
Adjudicated diagnoses.
Patients presenting to the
emergency department in
whom serial cTnIs were
measured.
280 106 (37.9%) 174 (62.1%) Ortho-Clinical
Diagnostics
VITROS ES cTnI.
LoD: 12 ng/l
99th URL: 34 ng/l
10% CV: 34 ng/l
El-Haddad
(40)
Type 2 MI caused by ischemia from
increased oxygen demand or
decreased supply.
Diagnoses assigned on chart review.
Examined charts of all patients
>18 yrs and older with a
cTnI 1.6 ng/ml.
807 512 (63.4%) 295 (36.6%) Beckman Access cTnI.
Values 1.6 ng/ml
were considered
abnormal.
Smith (18) Type 1 MI is ACS and type 2 MI is
a result of a supply/demand
mismatch from other acute illness.
Both types have elevated cTn with
rise and/or fall. Adjudicators
blinded to the purpose of the study
reviewed all patient data and
assigned diagnoses of type 1 or 2
MI, or no MI.
Retrospective review of
consecutive ED patients with
ischemic symptoms in whom
cTnI was obtained
139 40 (28.8%) 99 (71.2%) Siemens Stratus
CS cTnI
LoD: 40 ng/l
99th URL: 99 ng/l
10% CV: 150 ng/l
Continued on the next page
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2083Prognosis
There is limited data regarding outcomes of patients with
T2MI. The most robust analysis comes from the TIMI
group and the TRITON–TIMI 38 trial in which, even afteradjusting for clinical covariates, all subtypes of MI were
associated with an increased risk of cardiovascular death
(34). T2MI had a 3-fold increased risk (adjusted hazard
ratio [HR]: 2.8; 95% conﬁdence interval [CI]: 0.9 to 8.8;
Table 1 Continued
Fisrt Author
(Ref. #) Type 2 MI Study Deﬁnition Studied Population
Total
MIs
T1MI,
n (%)
T2MI,
n (%)
Troponin Assay:
Category
(LoD, 99th URL, CV)
Bonaca
(41)
Adjudicated diagnoses according
to the Universal Deﬁnition of MI
deﬁning type 2 as secondary/
demand.
Enrolled patients 18 years
of age who presented
within 24 hours of onset
of non-traumatic chest pain
suspicious for ACS.
96 86 (90%) 10 (10%) Siemens Centaur cTnI.
LoD: 30 pg/ml.
Established cut-point
of 100 pg/ml with
a total imprecision
of 20% at that
concentration.
Smith
(22)
Central adjudicators indicated
whether the AMI was type 1 or 2
MI. Type 2 AMI if at least 2 of 3
adjudicators gave that diagnosis.
Central adjudicators were trained
in the 2007 AMI criteria.
Patients at least 18 years of
age with symptoms of ACS in
whom objective testing within
7 days for coronary disease
assessment was planned,
deﬁned as any type of stress
testing, or invasive or
computed tomographic
coronary angiography.
134 127 (95%) 7 (5%) Multicenter study
with different
cTn assays.
Szymanski
(20)
AMI was diagnosed when there was
a rise/fall in cTn above the 99th
percentile (at least 1 value), with
symptoms or electrocardiography
patterns speciﬁc for ischemia.
Type 2 MI was diagnosed when there
were no signs of hemodynamically
signiﬁcant stenosis of
atherosclerotic origin in coronary
arteries. Etiology of the infarction
(coronary artery spasm, anemia,
arrhythmia, coronary embolism,
hypertension, or hypotension) was
established based on the medical
records, with use of speciﬁc
objective criteria for leading
mechanisms.
Retrospective analysis of
2,882 consecutive patients
presented to the ED with
an initial diagnosis of ACS.
Excluded Takotsubo,
myocarditis, cardiac
amyloidosis/sarcoidosis,
pulmonary embolism,
previous surgical operation,
or trauma.
2,882 2,824 (98%) 58 (2%) Details on cTn assay
not reported.
Stein
(21)
Diagnosis of type 1 and type 2 MI
were at the discretion of the
treating physician. To ensure
compliance with the deﬁnition,
a retrospective validation of the
diagnosis of all type 2 MI was
performed independently by 2
expert physicians. Patients for
whom a speciﬁc valid cause for
type 2 MI was not established
were re-classiﬁed as type 1 MI.
Prospective nationwide data
collection of patients with
ACS in Israel. Israeli Heart
Society is responsible for data
collection, and since 2008 the
survey has implemented the
universal deﬁnition of MI.
Analysis performed on
patients with type 1 and 2 MI
who participated in 2
prospective national surveys
performed in 2008 and 2010.
2,818 2,691 (95.5%) 127 (4.5%) Details on cTn assays
not reported.
Percentages shown are based on total MI denominator.
ACS ¼ acute coronary syndrome(s); AMI ¼ acute myocardial infarction; cTn ¼ troponin; CV ¼ coefﬁcient of variation; ED ¼ emergency department; ICD ¼ International Classiﬁcation of Diseases; LoD ¼
limit of detection; MI ¼ myocardial infarction; NR ¼ not reported; URL ¼ upper reference limit.
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2084p ¼ 0.085). The cumulative incidence of cardiovascular
death at 180 days was comparable between T1MI and T2MI
(8.3% vs. 7.3%). T2MI had signiﬁcantly worse mortality rates
when compared with no MI (7.3% vs. 1.3%, p < 0.001).
Our group recently showed that 180-day mortality rates
were similar among NSTEMI (T1MI) (17%) and T2MI
(24%), but mortality rates for both were increased (each
p < 0.001) compared with patients having no MI and
normal cTnI at baseline (4.9%) (19).
Further research is required to validate these ﬁndings
and conﬁrm if T2MI has worse outcomes independent of
other comorbidities, such as renal and heart failure, andindependent of the severity of the underlying illness that
resulted in T2MI.Management
There are no formal guidelines available regarding the ma-
nagement of T2MI. Despite its incidence and association
with worse outcomes (12,34), there are no guidelines
addressing the acute or long-term management of this entity.
This absence of guidance is likely to result in variable clinical
decision-making when dealing with T2MI, which could
lead to wide variations in cost-effectiveness and resource
Table 2
Controversies Open for Discussion Pertaining to
Type 2 MI
Should all clinicians embrace the 5-MI subtype classiﬁcation and therefore
increase the recognition of T2MI? Or should we advocate for the more familiar
ACS classiﬁcation, which is clinically used to guide reperfusion and
pharmacological treatment, and otherwise utilize a “non-ACS” label that includes
supply/demand MI?
Should the ICD codes recognize T2MI to facilitate quality review evaluations,
including resource utilization and outcomes assessments?
Given the inclusion of coronary endothelial dysfunction as one of the conditions to
consider when encountering T2MI, does this imply that there should be a role for
pursuing endothelial-dependent coronary ﬂow reserve assessment with
acetylcholine in the acute MI setting? Or should this be a diagnosis of exclusion?
Given the challenges surrounding the clinical distinction between T1MI and T2MI,
should there be a “default” diagnosis when diagnostic uncertainty prevails, with
consequential clinical and research implications?
What are the implications of applying terms such as NSTEMI and STEMI, which
have been traditionally used to guide revascularization and pharmacological
treatment in T1MI (ACS) to T2MI?
Should strict and standardized criteria be used to deﬁne T2MI? Or should an
individualized approach assessing all involved variables be favored?
Should clinicians preferably order cTn on patients with a higher pretest probability
for T1MI? Or should cTn be obtained in all-comers with suspected ischemic
symptoms besides chest pain (e.g., dyspnea, abdominal pain) and lower pretest
probability for T1M1?
Should studies include a more selected, homogeneous, ischemic chest pain
population, or an unselected population with various symptoms suggestive of
ischemia to allow reproducibility and comparison?
Do T2MI have independently worse outcomes? Or is this a reﬂection of the
underlying unadjusted comorbidities?
If there is no prior diagnosis or evaluation, should patients with T2MI be considered
for CAD and structural heart disease evaluation?
ACS ¼ acute coronary syndrome(s); CAD ¼ coronary artery disease; ICD ¼ International Classiﬁ-
cation of Diseases; MI ¼ myocardial infarction; NSTEMI ¼ non–ST-segment elevation myocardial
infarction; STEMI ¼ ST-segment elevation myocardial infarction; T1MI ¼ type 1 myocardial
infarction; T2MI ¼ type 2 myocardial infarction.
Table 3
Recommendations on Supply/Demand Type 2 MI
Based on Literature Review and Author’s Opinion
Supply demand T2MI should be diagnosed when there is evidence of myocardial
necrosis in a clinical setting consistent with an acute supply/demand imbalance,
without plaque rupture, in which there is a rise and/or fall of cTn with at least 1
value >99th upper-reference limit, plus at least 1 other MI criteria according to
the Universal Deﬁnition of MI.
In the absence of other underlying conditions that lower the ischemic threshold
(e.g., ﬂow-limiting CAD), an evident acute and/or sustained supply/demand
imbalance must be present.
In the presence of underlying conditions that lower the ischemic threshold, an
individualized diagnostic approach assessing all contributing variables seems
reasonable.
Clinicians and researchers should report the “altered” variable (s) within the
supply/demand balance. There can be either a single predominant cause or
multiple contributing variables. If one cannot readily identify any clear “alternate”
factor that would alter the supply/demand balance, one must be cautious before
labeling an MI as type 2.
If the T1MI and T2MI distinction is equivocal, expert consultation should be
considered before empirically initiating usual T1MI (ACS) therapies, largely
because of risks associated with such therapies.
In angiographically “normal” patients with an MI diagnosis, careful clinical
judgment should be made to clarify if a patient should be diagnosed and treated
as T1MI, particularly if no clear “alternate” supply/demand imbalance is
identiﬁed. Further evaluation to clarify the etiology of myocardial necrosis should
be considered (e.g., cardiac MRI).
For diagnostic purposes, cTn measurements should be performed in cases in which
T1MI (ACS) is suspected. The consequences of testing a broader unselected
population may have resource utilization, therapeutic, and ﬁnancial implications,
which are not well understood.
T2MI must be recognized by the ICD codes to facilitate quality review evaluations,
including resource utilization and outcomes assessments.
Among patients with T2MI, in which the index event appears to be related to
underlying undiagnosed CAD, further evaluation for CAD or structural heart
disease should be considered.
MRI ¼ magnetic resonance imaging; other abbreviations as in Table 1 and 2.
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2085utilization. It has been proposed that aspirin and beta-blockers
may have a role in T2MI (35). There is an urgent need for
evidence-based diagnostic and therapeutic strategies, pri-
marily randomized, controlled clinical trials. Until data from
appropriate clinical trials are available, there will continue
to be wide variability in the management of these patients.
Furthermore, T1MI and T2MI may not be easily
distinguished, which may lead to erroneous initiation of
T1MI (ACS) guideline-driven therapies in patients with
T2MI (5,6,14). At present, most clinicians would agree
that for T2MI, one must treat the underlying etiology and
correct the altered variable within the myocardial oxygen
supply/demand balance.
Among patients with cTn increases in the intensive care
unit, it has been proposed that if the event appeared to be
related to underlying CAD, further evaluation for CAD
(invasive or noninvasive) or structural heart disease should be
considered (2,36). This is a reasonable approach in similar
clinical situations, even outside the intensive care unit setting.Current Controversies and Future Steps
Supply/demand MI is a matter of discussion and controversy
in both clinical practice and research trials for several reasons(Table 2). First, it is unclear if most clinicians have embraced
the Universal Deﬁnition of MI. Second, despite recognition
of T2MI by the cardiology societies, there is no clear con-
sensus regarding the exact deﬁnition of T2MI. The current
deﬁnition is vague, leading to subjectivity in the diagnosis.
Clinicians and researchers may need to develop a standar-
dized, detailed deﬁnition to facilitate the consistent analysis
of clinical ﬁndings.
Third, in the United States, where Centers for Medicaid
and Medicare Services and National Center for Health
Statistics uses the International Classiﬁcation of Diseases
codes, it must be emphasized that despite the recognition
of this disease by the major societies, the Universal Deﬁni-
tion of MI subtypes remain ignored. This is of great concern
because clinicians are unable to diagnose a patient with
T2MI without being penalized by International Classiﬁca-
tion of Diseases coders for deviating from the accepted
guideline-driven ACS therapies that are required by Centers
for Medicaid and Medicare Services (e.g., aspirin on arrival
and discharge, beta-blocker, statin prescribed on discharge,
and so on), even though these therapies might not be
appropriate for T2MI.
Finally, there are several circumstances in which the
distinction between T1MI and T2MI might be uncertain,
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adjudication may be difﬁcult. In this context, it is contro-
versial about whether to default to T1MI until proven
otherwise, or vice versa. This clinical distinction is usually
done by coronary angiography; however, up to 15% of pa-
tients undergoing catheterization for suspected CAD have
angiographically “normal” coronaries, and intravascular ul-
trasound may often detect occult disease in these patients
(37–39). Thus, although visualization of a culprit lesion on
angiography is often required to deﬁne a T1MI by clinicians
and/or researchers, it may result in misclassiﬁcation.
Research data over the next several years will demon-
strate the growing occurrence of T2MI. Anticipating future
guidelines addressing in detail the complexity behind T2MI
to guide clinicians and researchers, we propose our insights
in Table 3 as a starting point for discussion.
Conclusions
Supply/demand T2MI is a commonly encountered clinical
challenge, and it is anticipated that it will be detected even
more once high-sensitivity cTn assays are approved for
clinical use in the United States. Understanding the basic
concepts involved in myocardial oxygen supply and demand
will facilitate the diagnosis and treatment of patients with
increased cTn values. Future efforts are required to consol-
idate the deﬁnition of T2MI to bring consistency to this
diagnosis in clinical practice, adjudicated research studies,
and clinical trials, as well as for regulatory compliance.
Studies are urgently required to produce evidence-driven
classiﬁcation, which will assist in management guidelines.
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